Longer prostate cancer-specific survival seen for specific subgroups, including those with the CYP1A2 AA genotype
THURSDAY, Sept. 22, 2022 (HealthDay News) — High coffee intake is associated with longer prostate cancer-specific survival (PCSS) for certain subgroups of men, including those with the CYP1A2 AA genotype, according to a study published online Aug. 19 in European Urology Oncology.
Justin R. Gregg, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues examined the associations between coffee intake, caffeine metabolism genotype, and survival using data from the PRACTICAL Consortium database for 5,727 men with prostate cancer. Cases had data available for the CYP1A2 163C>A rs762551 single-nucleotide variant associated with caffeine metabolism, coffee consumption, and follow-up of more than six months.
The researchers found that although the results were not statistically significant, high coffee intake seemed to be associated with longer PCSS and overall survival. High coffee intake was associated with longer PCSS among men with clinically localized disease, with similar, but not statistically significant, results among those with advanced disease. Among men with the CYP1A2 AA genotype, high coffee intake was associated with significantly longer PCSS; no associations were seen for men with the AC/CC genotype. In subgroup analyses, there were no associations observed for overall survival.
“Future work is needed to replicate these findings, to determine the specific populations (such as those with a fast caffeine metabolism genotype) in which coffee-based interventions or coffee intake ‘prescriptions’ could be beneficial, and to define the mechanisms through which coffee- and caffeine-related metabolites impact prostate cancer progression,” the authors write.
One author disclosed financial ties to Bayer.
Copyright © 2022 HealthDay. All rights reserved.
